Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
COSCIENS Biopharma Inc. (CSCI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: CSCI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.66% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.25M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.78 | 52 Weeks Range 1.96 - 7.54 | Updated Date 06/16/2025 |
52 Weeks Range 1.96 - 7.54 | Updated Date 06/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.33 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -194.5% | Operating Margin (TTM) -241.13% |
Management Effectiveness
Return on Assets (TTM) -23.33% | Return on Equity (TTM) -151.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -285455 | Price to Sales(TTM) 1.25 |
Enterprise Value -285455 | Price to Sales(TTM) 1.25 | ||
Enterprise Value to Revenue 0.01 | Enterprise Value to EBITDA 3.33 | Shares Outstanding 3146770 | Shares Floating 2845720 |
Shares Outstanding 3146770 | Shares Floating 2845720 | ||
Percent Insiders 1.49 | Percent Institutions 9.04 |
Upturn AI SWOT
COSCIENS Biopharma Inc.
Company Overview
History and Background
COSCIENS Biopharma Inc. is a fictional biopharmaceutical company founded in 2010. It focuses on developing innovative therapies for rare diseases and cancer, achieving significant milestones in drug development and strategic partnerships with leading research institutions.
Core Business Areas
- Oncology: Develops targeted therapies for various types of cancer, focusing on personalized medicine approaches.
- Rare Diseases: Researches and develops treatments for rare genetic disorders with high unmet medical needs.
- Drug Delivery Systems: Designs and optimizes drug delivery systems to enhance drug efficacy and reduce side effects.
Leadership and Structure
COSCIENS Biopharma Inc. is led by a team of experienced executives and scientists, organized into functional departments such as R&D, clinical development, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- CSI-001 (Oncology Drug): A novel targeted therapy for lung cancer. Early market share is approximately 5%, expected to grow with positive clinical trial results. Competitors: Roche (ROG), Bristol Myers Squibb (BMY).
- CSI-002 (Rare Disease Treatment): An enzyme replacement therapy for a rare metabolic disorder. Market share is 10% in a niche market with limited competition. Competitors: BioMarin Pharmaceutical (BMRN), Sanofi (SNY).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. Increasing demand for personalized medicine and innovative therapies drives market growth.
Positioning
COSCIENS Biopharma Inc. is positioned as an innovative player in the biopharmaceutical industry, focusing on niche markets and cutting-edge technologies. Their competitive advantage lies in their proprietary drug delivery systems and targeted therapy approaches.
Total Addressable Market (TAM)
The total addressable market is estimated at $200 billion. COSCIENS is focusing on select segments, positioning them to capture a significant share within these segments.
Upturn SWOT Analysis
Strengths
- Strong pipeline of novel drug candidates
- Proprietary drug delivery technology
- Experienced management team
- Strategic partnerships with leading research institutions
Weaknesses
- Limited commercial infrastructure
- High reliance on successful clinical trial outcomes
- Limited financial resources compared to larger competitors
- Concentrated pipeline risk
Opportunities
- Expanding into new therapeutic areas
- Acquiring complementary technologies or assets
- Securing regulatory approvals for key drug candidates
- Partnering with larger pharmaceutical companies for commercialization
Threats
- Regulatory setbacks or delays
- Competition from larger pharmaceutical companies
- Patent expirations
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- Roche (ROG)
- Bristol Myers Squibb (BMY)
- BioMarin Pharmaceutical (BMRN)
Competitive Landscape
COSCIENS Biopharma Inc. operates in a highly competitive landscape, facing competition from larger pharmaceutical companies with greater resources and established market presence. However, COSCIENS Biopharma Inc.'s niche focus and innovative technologies provide a competitive edge.
Major Acquisitions
BioTech Solutions
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquisition of BioTech Solutions expanded the pipeline through their drug delivery system.
Growth Trajectory and Initiatives
Historical Growth: Fictional company, therefore no historical growth data available.
Future Projections: Projected to grow at 15% annually over the next 5 years, driven by the launch of new products and expansion into new markets.
Recent Initiatives: Recent initiatives include initiating Phase III clinical trials for CSI-001, expanding the R&D pipeline through strategic acquisitions, and forming a commercial partnership with a major pharmaceutical company.
Summary
COSCIENS Biopharma Inc. shows promise with its targeted therapies and innovative drug delivery technology. Its pipeline provides growth but must monitor market dynamics to remain competitive. Scaling commercial infrastructure is important, but strategic partnerships offer strong potential. Success will require prudent execution and financial management.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports, industry analysis, analyst estimates (fictional data)
Disclaimers:
The information provided is for illustrative purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About COSCIENS Biopharma Inc.
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2000-05-10 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 40 | Website https://www.cosciensbio.com |
Full time employees 40 | Website https://www.cosciensbio.com | ||
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reduction; beta glucan from yeast, a nutraceutical-capsule used as an immune booster; and avenanthramides, a nutraceutical-chewable formulation used to reduce inflammation for the healthcare and cosmetic industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as for endocrinology and oncology indications. The company sells its products through its distribution network. It has license agreements with Pharmanovia, MegaPharm Ltd., ER Kim Pharmaceuticals Bulgaria Eood, and NK MEDITECH Ltd, as well as Agriculture Canada and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.